biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > Consequences of a "no" vote: from IR

<< Previous

Bullboard Posts

Next >>

Comment by OttawaPeteron Jan 19, 2023 8:38pm

113 Views

Post# 35234621

RE:RE:RE:RE:RE:Consequences of a "no" vote: from IR

G1945V wrote:
G1945V wrote:
zwerp2000 wrote: So i am confused. If xB3 is really worth so much, how come BTI could not find a partner to help develop it and save them? Surely if there was any value to xB3, they could have found someone to partner with, no? Doesn't make sense to have such a valuable asset and have pretty much no one interested in using it after all of these years

Well, thank goodness Midatech Pharma PLC seems to have found some value in xB3!

G1945V

This could very well end up a YES vote from the BTI shareholders and a NO from Midatech Pharma PLC shareholders which would put BTI on the lurch. I wonder if this concern is in the minds of BTI management.

Midatech dropped by more than half of its December 12, 2022 share balance price when it was $1.65 US.

JMO
G1945V